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Abstract
Background Early detection of colorectal cancer decreases the risk of mortality. Faecal occult blood tests (FOBT) are recognised
as a useful tool for colorectal cancer screening. These non-invasive, rapid, and easy-to-carry assays are very often used as a point-
of-care test and for self-testing. On the market, there are various types of FOB tests available, including chemical and
immunochromatographic tests, which are based on different detection methods and differ in their sensitivity and specificity.
Conclusions Clinicians should be aware of the causes of false-negative and false-positive test results, which can vary depending
on the test. Additionally, stool sampling bias may be a source of error and must be considered by the clinician. The current FOBT
methods are subject to various interfering factors; items such as proper preparation of the patient prior to testing or the clinician’s
knowledge of testing limitations are key in correct interpreting results. Novel technologies such as FOBTDNA tests, micro RNA
tests, and biochips equipped with bacteria can indicate bleeding from the gastrointestinal tract and improve diagnostics process.
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Introduction
Faecal occult blood tests (FOBT) are used to detect blood in a
stool which is not macroscopically visible [1, 2]. These tests
are primarily performed as a first-line screening test for colo-
rectal cancer (CRC), which is the third most common cancer
in the world behind lung and breast cancer [2, 3]. According to
statistics from the American Cancer Society (ACS), an esti-
mated 140,250 new cases and 50,630 deaths from CRC are
expected to occur in 2018. The risk of developing colorectal
cancer is estimated as 1 per 22 (4.49%) for men and 1
per 24 (4.15%) for women, with case prognosis being strongly
dependent on early detection of disease [4]. Therefore, the
ACS recommends annual stool-based screening for persons
over the age of 45 regardless of gender who have an average
risk of CRC. Average risk is defined by the following patient
characteristics: having no personal history of CRC, certain
types of polyps, inflammatory bowel disease, or receiving
radiation treatment to the abdomen or pelvic area to treat a
prior cancer; no family history of colorectal cancer; and no
evidence of confirmed or suspected hereditary colorectal can-
cer syndrome [5]. FOBT is a non-invasive, painless, inexpen-
sive method that can be performed by the patients themselves
at home [6].
There are currently three types of FOBTs based on different
measurement methods: chemical tests, immunochromato-
graphic tests, and DNA tests, which are not commonly avail-
able. These tests differ not only in the detection method but
also in their susceptibility to cross-reactions and interfering
factors [1, 7, 8]. Regardless of the test in use, clinicians should
inform patients about contraindications. FOBTs should not be
performed on patients experiencing menstruation, bleeding
from haemorrhoids, or bleeding from the urinary tract due to
the risk of contamination of stool with blood from these areas.
Failure to follow these guidelines may lead to false-positive
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results. It should be also noted that the result of FOBT
cannot be the basis for making clinical decisions. Positive
results should be followed by an endoscopic examination [9,
10].
Comparison of FOBTs
There are two types of chemical FOBT. The first is guaiac
FOB (gFOB) testing, which is a qualitative assessment of
the pseudo-peroxidase activity of haem from haemoglobin
molecules found in faecal blood. Detection of blood in the
stool occurs when blood-derived haemmediates the oxidation
of guaiac acid by hydrogen peroxide into guaiac blue [7, 11].
The gFOB test is limited by a high risk of false-positives
results [12]. Before performing a gFOB test, the patients
should be instructed on how to properly prepare themselves
[12, 13]. It is important that the patient avoids consumption of
red meat along with certain vegetables and medicines for a
minimum 2 to 7 days prior to the test [12, 14]. False-positive
results may be caused by the presence of animal-derived
haem, consumption of large amounts of green vegetables
which may have chlorophyll-mediated pseudo-peroxidase ac-
tivity and other foods (due to the naturally high levels of
peroxidase) (broccoli, cauliflower, cantaloupe, carrots,
squashes, figs, horseradish, grapefruit, melons, tomatoes,
pumpkins, courgettes, etc.), or medicines including NSAID,
vitamin C, and iron [13–15]. These requirements can be dif-
ficult for the patient and therefore the diagnostic specificity of
the guaiac test is low, reaching only 50% [13].
An alternate to gFOB testing is 3,3′,5,5′-tetramethylbenzi-
dine (TMB) testing. The TMB test is a one-stage test usually
used as a pads (test papers) [15]. Paper soaked with the
TMB indicator should be placed in a toilet bowl just after
defaecation [16]. In this test, haem derived from free
haemoglobin, lysed erythrocytes, or myoglobin catalyses
the oxidation reaction of the indicator in an aqueous envi-
ronment and triggers the test paper to change colour after
2 min into a green or blue colour [16]. While the perfor-
mance of this test is simple and convenient for patients, the
test only detects the blood present in the external layer of the
stool. Similar to the gFOB test, TMB FOBTs are also vul-
nerable to interfering factors and the patient should exclude
red meat, medications, green vegetables, and citrus fruit
from the diet at least 3 days prior to testing [15, 16].
Furthermore, reading the results of the test is not objective
as the patient must decide whether the colour change is
adequate. This could be confusing and may lead to an im-
proper interpretation of the test results, especially if the pa-
tient reads the test result from a distance.
The other groups of FOBTs are immunochemical tests
(iFOBT or FIT—faecal immunochemical test), which detect
a human globin, a protein that is a component of haemoglobin
using specific antibodies [14, 17]. There are two types of
iFOBT: qualitative, point-of-care tests and quantitative, auto-
mated tests [18]. Quantitative iFOB tests measure concentra-
tion of haemoglobin in a stool sample on an automated
analyser. Although they provide detailed results, they can only
be performed in a medical laboratory [18]. Qualitative iFOB
tests, which are used at point of care, are usually prefabricated
cassettes where results are read by visual inspection. A
coloured band appears in the test patch if the haemoglobin is
present in the faeces. It is important to remember that tests
supplied by differentmanufacturers have different sensitivities
to haemoglobin concentration in the stool [19]. After
defaecation, samples should be collected from several places
of the stool including inner parts and mixed with buffer prior
to application onto the testing area of the cassette [19]. The
main advantage of the iFOBmethod is the lack of interference
from animal haemoglobins or fruit and vegetable compounds,
allowing the patients to maintain their normal diet. Also, pa-
tients do not need to discontinue drugs which commonly in-
terfere with the gFOB method [14].
Nowadays, researchers are continuously working on the
development of new technologies which will significantly im-
prove the efficiency and accuracy of FOB detection. Recently,
Mimee et al. have described an ingestible sensor equipped
with genetically engineered bacteria which can indicate bleed-
ing in the gastrointestinal tract. Authors reported that biomo-
lecular monitoring of the gut might be precise and faster than
other laboratory methods [20].
The knowledge about test limitation and possible interfer-
ences is a key point for proper screening [12]. Generally, the
iFOB test is more specific than gFOB test and not subject to
the interfering factors like gFOBT [14]. Studies which com-
pared the specificity and sensitivity of the commercially avail-
able FOB tests have demonstrated that iFOB testing maintains
an advantage over the available chemical tests in the ability to
detect CRC [21]. A recent US study which involved 5841
patients has shown that iFOB tests were able to detect
81.8% of individuals with invasive CRC, while the gFOB test
detected only 64.3% of CRC cases. Additionally, the specific-
ity of these tests for CRC detection was 96.9% for iFOB
testing and 90% for gFOB testing [22]. In Germany, six dif-
ferent commercially available iFOBTs were compared with
the gFOBT. The researchers examined 1319 patients with risk
for CRC, with the iFOBTs demonstrating 97% specificity and
gFOBT 95%. The summary diagnostic sensitivity was 50%
for the iFOBTs and 30% for the gFOB test [23]. A study
performed by Cruz-Correa et al. compared gFOB and TMB
testing and demonstrated that while the guaiac test is
characterised by both higher specificity and sensitivity, pa-
tients preferred the test with TMB (tissue pad), considering
it to be more comfortable and easier to perform [24].
Comparing iFOB testing, sampling requires fewer episodes
than chemical testing, but due to the modern construction of
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the toilet bowls where the faeces drop directly into the drain,
the correct sample collection is very difficult. The stool sam-
ple may be contaminated with residues of previous
defaecations and urinations, chemical toilet cleaners, disinfec-
tants, and fragrances [25]. The typical method of proper stool
collection can be uncomfortable, as the excrements must be
collected using a plastic container. Specially designed con-
tainers for stool collection that are more user-friendly are also
available [24].
Doctors should also remember that chemical FOB tests
could be positive in the cases of bleeding from all parts of
GI tract, whereas the diagnostic value of iFOBT is limited to
the detection of bleeding from the lower gastrointestinal tract
since globin from the upper GI is readily degraded by diges-
tive proteolytic enzymes [26]. This was confirmed by a study
which demonstrated that up to 100 mL of ingested blood went
undetected by some immunochemical methods but was de-
tected by gFOBT [26–28]. There have been numerous cases
of massive bleeding from the stomach and duodenum, with
tarry stools, where the iFOBT gave negative results due to
digestion of the globin during passage through the gastroin-
testinal tract. In the case of tarry stools (after excluding the
therapy with coal, consumption of berries, swallowing blood
from nosebleeds, etc.) and the negative iFOBT, the upper gas-
trointestinal bleeding should be suspected [16]. Moreover,
iFOBTs are not clinically specific to CRC. Non-neoplastic
and benign pathologies may also bleed and give positive test
results [28, 29].
Other Alternative and Non-invasive Tests
for CRC Screening
Several promising new technologies for CRC detection
are currently in development. Multitarget faecal DNA
and RNA assays are novel but are currently limited by
high costs [10, 30]. These tests are based on detection
of key mutations occurring during early stages of colon
carcinogenesis including K-Ras, adenoma polyposis coli
(APC), and p53 as well as epigenetic changes like a mi-
crosatellite instability. Furthermore, the second generation
of stool DNA tests include analysis of methylated genes
for vimentin, secreted frizzled-related protein 2 (SFRP2),
bone morphogenetic protein 3 (BMP3), N-Myc down-
stream-regulated gene 4 protein (NDRG4), and tissue fac-
tor pathway inhibitor 2 (TFPI2) [29–34]. Recently, studies
have shown that the DNA marker panels have a diagnos-
tic sensitivity for detection of CRC of 92.3% and for
precancerous lesions of 42.4%. Diagnostic specificity for
these panels ranges from 86.6 and 94.9% [35]. These
findings demonstrate an advantage for this test over colo-
noscopy in detecting ascending colon lesions. The re-
searchers who carry out these studies plan to reduce
DNA test costs and implement them as point-of-care di-
agnostics as a lab-on-chip or microarrays. A novel test
involving detection of faecal microRNAs, a group of
18–25 nucleotide non-coding RNA molecules which reg-
ulate gene expression, is also in development. According
to authors, this assay is an effective screening method,
which may detect the presence of adenomas, advanced
adenomas, and CRC with 62%, 73%, and 78% sensitivi-
ties respectively [36].
Summary
The currently recommended FOBT for CRC screening is
the iFOB test, performed annually. This test is, however, a
preliminary examination and the diagnosis of colon can-
cer requires additional tests such as colonoscopy or sig-
moidoscopy with a collection of a biopsy section for fur-
ther pathomorphological and genetic examinations. In the
case of bleeding from the upper gastrointestinal tract,
there is currently a lack of high-sensitivity assays, al-
though such bleeding can be detected by guaiac or TMB
tests. These tests are sensitive to numerous interfering
substances, and if there is a suspicion of bleeding from
the upper or lower gastrointestinal tract, the results should
be confirmed by gastroscopy and/or colonoscopy. Due to
the wide availability of various kinds of FOBTs, physi-
cians should pay attention to which tests they recommend
to patients and what method is used when patients report
results of self-testing. In the case of gFOB and TMB FOB
tests, the clinician should discuss diet with the patient
because diet is the main source of false-positive results.
Also, the sampling procedures using commercially avail-
able devices should be presented to the patient.
Developing new screening tests for CRC may improve
the efficiency of its detection and therefore significantly
limit mortality. Non-invasive testing may be a first-line
screening option for asymptomatic individuals at average
risk for CRC.
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